Clinical Trial Update: Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated sargramostim (Leukine) to reduce oral mucositis in patients undergoing radiation therapy for head and neck cancer; the study has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Radiation Therapy Oncology Group | Conditions: Head and Neck Cancer, Oral Complications | Phase 3 | Status: COMPLETED